Why Arrowhead Pharmaceuticals Stock Is Diving Today

Arrowhead Pharmaceuticals Inc ARWR shares are down 20% Monday after the company announced topline results from the SEQUOIA Phase 2 study of fazirsiran in patients with alpha-1 antitrypsin deficiency-associated liver disease.

What To Know: Fazirsiran is a potential first-in-class investigational RNA interference therapy designed to reduce the production of mutant alpha-1 antitrypsin protein as a potential treatment for rare genetic liver disease.

Patients receiving 25 mg, 100 mg, or 200 mg of fazirsiran demonstrated a dose dependent mean reduction in serum mutant alpha-1 antitrypsin protein concentration at week 48 of 74%, 89%, and 94%, respectively. All three doses led to a dramatic reduction in total liver Z-AAT with a median reduction of 94%

"Currently there is no treatment for liver disease from alpha-1 antitrypsin deficiency. The results presented today from the SEQUOIA study are highly encouraging to physicians and patients in need of a safe and effective therapy for this rare genetic condition," said Virginia Clark, M.D., M.S., University of Florida, Division of Gastroenterology, Hepatology, and Nutrition.

This month, the company plans to initiate a randomized, double-blind, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of fazirsiran in the treatment of alpha-1 antitrypsin deficiency–associated liver disease with METAVIR stage F2 to F4 fibrosis.

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.

See Also: US Stocks Look Set To Carry Last Week's Momentum Forward On Monday

ARWR Price Action: Arrowhead has a 52-week high of $61.25 and a 52-week low of $26.81.

The stock was down 20.1% at $29.88 at time of publication, according to Benzinga Pro.

Photo: Gerd Altmann from Pixabay.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: MoversTrading Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!